Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis
Information source: Laboratoires Thea
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Seasonal Allergic Conjunctivitis
Intervention: T1210 (Drug); Olopatadine hydrochloride (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Laboratoires Thea
Summary
The aim of this study is to compare the efficacy and the safety of T1210 versus Olopatadine
eye drops in the topical treatment of seasonal allergic conjunctivitis.
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Primary outcome: Change from baseline of the score of tearingChange from baseline of the score of itching Change from baseline of the score of conjunctival hyperaemia
Secondary outcome: Global local tolerance assessment by the Investigator and the patientGlobal local tolerance assessment by the Investigator and the patient
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Written informed consent
- Conjunctivitis allergic conjunctivitis
Exclusion Criteria:
- Severe ocular allergy
- Vernal keratoconjunctivitis
Locations and Contacts
Pierre Huguet, Clermont ferrand 63000, France
Additional Information
Starting date: April 2011
Last updated: April 11, 2012
|
